Eva Kalias started working for Santhera in 2014 as a PR consultant. In 2018, she joined the Company with responsibility for external communications and since May 2022, she acts as Head Investor Relations & Communications.

Prior to that, she managed and marketed private equity investments in pharma and biotech on behalf of Swiss Life. Additionally, she was in charge of the communications activities (investor and media relations) of the company's private equity business. Previously, Eva headed the investor relations teams of Alusuisse Lonza Group, Ciba Speciality Chemicals and Ciba-Geigy (today Novartis). She was responsible for the worldwide investor relations activities of these companies and was involved in strategic projects like M&A transactions, spin-offs and crisis communications. With her IR teams, she was awarded Best Continental European Company for Investor Relations (1993) and Runner-up for Best Continental European Company (1995, 1996) by the Investor Relations Magazine, London.

Eva started her career as an international product manager for pharmaceuticals at Ciba-Geigy. She had marketing responsibility for taking a new cardiovascular drug from the clinical development stage to its successful global market introduction.

Eva graduated from the University of Zurich with a Master of Science degree in Biochemistry and holds an MBA degree from IMD in Lausanne, Switzerland.